Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Inclusion Criteria:

• Signed informed consent
• Biopsy proven neuroendocrine tumor, neuroblastoma, medulloblastoma, or othersomatostatin receptor positive tumor
• Off Sandostatin (octreotide acetate)-long acting release (LAR) > 4 weeks and offimmediate release (subcutaneous) for 12 hrs prior to 68Ga-DOTATOC PET-CT
• Karnofsky performance status or Lansky Play Scale status of >= 50 (or EasternCooperative Oncology Group [ECOG]/World Health Organization [WHO] equivalent)
• Subject is male; or is a female who is either pre-menarchal, surgically sterile (hashad a documented bilateral oophorectomy and/or documented hysterectomy),postmenopausal (> 1 years without menses), non-lactating, or of childbearing potentialfor whom a serum pregnancy test (with the results known prior to investigationalproduct administration) is negative; a negative serum pregnancy test will be requiredfor all female subjects with child bearing potential; if a false pregnancy test issuspected, e.g., perimenopausal condition, an obstetrician will be consulted todetermine if she is/is capable of becoming pregnant
• No therapy other than Sandostatin since last Octreoscan + diagnostic CT
• Fresh frozen (recommended) or paraffin fixed (required) specimen of primary ormetastases available for ribonucleic acid (RNA) and immunohistochemistry (IHC)

Exclusion Criteria:

• Pregnancy or breast feeding
• Surgical resection, chemotherapy, radiation therapy, or biologic therapy since lastOctreoscan + CT; continuation of the same dose of Sandostatin-LAR or subcutaneousSandostatin is allowed
• Medical condition uncontrolled by treatment making completion of study unlikely
• Weight more than 400 pounds (subjects who weigh more than 400 pounds will not be ableto fit inside the imaging machines)
• Inability to lie still for the entire imaging time (e.g. cough, severe arthritis,etc.)
• Inability to complete the needed investigational and standard-of-care imagingexaminations due to other reasons (severe claustrophobia, radiation phobia, etc.)
• Any additional medical condition, serious intercurrent illness, or other extenuatingcircumstance that, in the opinion of the investigator, may significantly interferewith study compliance